Background. Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for listeriosis. We investigated a potential association in cases of nonpregnancy-associated listeriosis using registry data.
Listeriosis is a bacterial, foodborne disease with the potential to cause serious infections such as septicemia and meningitis, with high case-fatality rates (25%-30%) [1] . Moreover, infection in pregnant women can be transmitted to the fetus and lead to abortion, stillbirth, or severe infection in the neonate. Known predisposing host factors include age >60 years, suppression of the immune system (eg, diabetes, cancer, immunosuppressive drugs), and pregnancy [2, 3] .
Since early 2000, several European countries, including Denmark, have reported increasing incidences of listeriosis [4] . Speculations as to what could be the cause of this trend include the escalating use of proton pump inhibitors (PPIs) [5] . In Denmark, the prescription rate for PPIs in those aged 40-64 years was 45.0 individuals per 1000 inhabitants in 2000; this increased by 250% to 113.3 per 1000 inhabitants in 2012 [6] . The hypothesis for this is that by elevating gastric pH, a natural host defense against Listeria monocytogenes would be reduced. Animal studies have shown this to be the case for rats [7] . Further, in observational studies, medications to suppress gastric acid and, in particular, PPIs have been identified as a potential risk factor for listeriosis [8] [9] [10] [11] [12] [13] , analogous to what has been observed for other enteric pathogens [14] [15] [16] [17] and community-acquired pneumonia (CAP) [18] . However, possible confounding by host factors questions the causality of such observed associations for enteric pathogens and CAP [19, 20] . Similarly, studies on listeriosis and gastric acid suppression potentially have suffered from selection bias [9, 10] , information bias [9, 10, 12] , lack of statistical power [11] , and lack of controlling for confounding host factors [12] .
In this study, we used Danish health registries and Danish listeriosis surveillance data to evaluate the association between PPI use and listeriosis. The study design provided the possibility to control for host factors and to minimize selection and information bias.
all Danish residents. The CPR number includes data on gender and date of birth and is issued by the Danish Civil Registration System (CRS), a national register that contains demographic and vital status data for all Danish residents [21] . From this register, we obtained home addresses, dates of migration to and from Denmark, disappearances, and dates of death. We also identified the source population from which we drew control participants.
In Denmark, cases of listeriosis are notifiable by diagnostic laboratories to Statens Serum Institut, which maintains the Danish Listeriosis Register (DLR). This register contains clinical and microbiological data on all cases reported since 1994 [22] . We defined a case of listeriosis as isolation of L. monocytogenes from a normally sterile site in a patient.
The Danish National Patient Registry (NPR) contains information, including discharge diagnoses, for all hospitalizations since 1977. Since 1995, the registry has included diagnoses from ambulatory contacts. Until 1994, discharge diagnoses were classified according to the International Classification of Diseases, Eighth Revision (ICD-8), thereafter ICD-10 [23] . For information on comorbidity, we extracted discharge diagnoses for cases and their matched controls during the 5-year period prior to cases' diagnosis of listeriosis.
The Danish Register of Medicinal Product Statistics (RMPS), established in 1994, contains information on all medicines sold in Denmark [24] . Medicines are categorized according to the Anatomical Therapeutic Chemical (ATC) Classification System. For prescription medicines, CPR number, date of redemption, strength, and quantity are among the variables included in the register. We extracted data on medicines prescribed 5 years prior to diagnosis of listeriosis for information on exposure, comorbidity, and potential confounders.
The Danish Data Protection Agency approved the study (journal 2012-54-0029).
Study Population
Eligible cases were Danish residents registered in the DLR with a diagnostic specimen that yielded L. monocytogenes taken from 1 July 1994 through 31 December 2012. We excluded known pregnancy-associated cases and cases aged <45 years in order to avoid the potential confounding effect of unregistered pregnancies. To obtain a homogenous study population, the age criterion also applied to men. Only first-time diagnoses of listeriosis were included. An index date for each case was set 7 days before the date of the diagnostic specimen in order to minimize any protopathic bias (when treatment for early symptoms of a disease appears to cause the disease). Using a risk-set sampling technique, we randomly selected up to 50 matched controls per case from the CRS [25] . We matched controls on sex, municipality and date of birth (we allowed for an age difference of up to 6 months), and calendar time, and assigned an index date equivalent to the index date of the case for whom they were controls. Controls were alive on the index date. Individuals were no longer eligible as controls from the date they became cases. With this sampling method, the odds ratio (OR) is used to estimate the incidence rate ratio [25, 26] .
Comorbidity
We created a comorbidity index (CMI) based on the principles described by Charlson et al. [27] to adjust for the influence of preexisting illness on the risk of listeriosis. In a Cox proportional hazards model, we analyzed data from all Danish residents registered in the NPR during 1994-2012 to calculate the hazard ratios (HRs) of listeriosis associated with each of the 31 diagnostic groups (Supplementary Table 1 ). HRs for these diagnostic groups were calculated simultaneously, thereby adjusted for the possible effect of one another and used as weights in further analyses where we created the index score by adding log-transformed weights. For each patient, a comorbidity index score was calculated as the sum of the weights corresponding to the number and severity of coexisting illnesses. We made 2 interdependent comorbidity indices stratified on 2 periods: from 5 years to 3 years (both years included) before the index date and from 2 years to 90 days before the index date. We set the limit at 90 days before the index date in order to avoid overlap with the exposure period. In constructing the CMI, we excluded any diagnosis of listeriosis and of peptic ulcers, diabetes, and alcoholism. Peptic ulcer was hypothesized to be associated with prescription of PPI and was included as an independent variable in the statistical analyses. The prevalence of diabetes and alcoholism could be underestimated using the NPR only, since this registry does not include diagnoses from general practice. Instead, diabetes was defined as use of antidiabetic medications and/ or diagnosis of diabetes in the 5 years before the index date. Similarly, we defined alcoholism as any use of drugs used in alcohol dependence and/or diagnosis of an alcohol-related disorder in the 5 years before the index date (Supplementary 2 for ATC and ICD codes).
Exposure Assessment
We defined use of a PPI as redemption of a prescription for PPI (ATC code A02BC). Current use of a PPI was defined as use 1-30 days before the index date and 2 additional exposure windows defined as the last redemption of a prescription 31-60 days and 61-90 days before the index date. Past use was defined as use 91-365 days before the index date. The exposure categories were mutually exclusive. The choice of exposure windows was based on analyses of redemption intervals, showing that most redemptions occurred in 14-, 30-, 60-, or 90-day intervals. In a supplementary analysis, we examined use of histamine-2-receptor antagonists (H2RA; ATC code A02BA) with the same exposure time intervals as defined above.
Potential Confounders
We examined a group of potential confounders that had known associations with PPI therapy, listeriosis, and/or concurrent conditions. Our analysis included CMI score; history of peptic ulcer, diabetes, or alcoholism; and prescription of nonsteroidal antiinflammatory drugs, antibiotics, systemic glucocorticoids, immunosuppressive drugs/immune modulating drugs, antineoplastic drugs, and/or H2RA as potential confounders (for ICD and ATC codes, see Supplementary Table 2 ). In the supplementary analysis of H2RA as exposure, we also included use of a PPI as a confounder.
Statistical Analyses
We estimated matched unadjusted and adjusted ORs with 95% confidence intervals (CIs) for PPI use in cases compared with controls using conditional logistic regression. We kept CMI score, peptic ulcer, prescription of systemic glucocorticoids, and prescription of H2RA as confounders in the statistical model, as they changed the OR estimate substantially. We examined effect-measure modification by sex, age group, CMI score, peptic ulcer, use of glucocorticoids, use of antibiotics, and time period. By use of natural cubic splines [28] , we estimated OR by time since the last PPI prescription redemption. The reference for all analyses was persons with no exposure in the 365 days prior to the index date. The population attributable fraction (PAF) was estimated using an equation for a potentially biased or confounded estimate [29, 30] .
In a sensitivity analysis, we used a CMI score where discharge diagnoses registered up to the index date were included; thus overlapping the exposure period. Furthermore, we calculated the association with listeriosis for use of bendroflumethiazide with potassium (referred to here as bendroflumethiazide; ATC code C03AB01), a thiazide diuretic that is widely used to treat hypertension in Denmark, with no a priori theoretical effect on the risk of listeriosis. For individuals aged ≥65 years, it was prescribed to approximately 200 per 1000 inhabitants in 2005-2012 [6] .
We used a significance level of 5%. All analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
For the 18½-year study period, we identified 819 eligible patients with listeriosis. We excluded 98 cases because of pregnancy or age <45 years. For the remaining 721 cases, we identified 50 controls for 93.9% and at least 10 controls for 98.9% of the cases. For 3 cases, no controls could be found. Overall, 34 844 matched controls were included in the analyses. Table 1 summarizes the characteristics of cases and controls. Patients with listeriosis were more likely than controls to have comorbid conditions and receive medications than controls.
Among cases and controls, 93 (12.9%) and 977 (2.8%) were current users of PPIs, respectively. The unadjusted OR for listeriosis associated with current PPI use was 6.21 (95% CI, 4.90-7.86) and the adjusted OR was 2.81 (95% CI, 2.14-3.69). The proportion of current users who were first-time users (within the last 365 days) was 37.2% and 22.1% (P<.001, χ 2 test) for cases and controls, respectively. Based on the adjusted OR for current use of PPI, the PAF of listeriosis due to PPI usage was estimated at 8.3%. Table 2 shows unadjusted and adjusted ORs for PPI use for all assessed exposure windows. The strength of association between PPI use and listeriosis was inversely proportional to days since last prescription redemption, as shown in Figure  1 . Modification of the CMI by including discharge diagnoses up to 1 day before the index date had a negligible effect on the OR estimates. In the analysis of exposure to H2RA, we found a positive, albeit nonsignificant, association between the use of H2RA and listeriosis (adjusted OR, 1.82; 95% CI, 0.89-3.71) for current use (Supplementary Tables 3 and 4) . Strength of association decreased with time before listeriosis diagnosis for H2RA as for PPI (Figure 1 ). We found no significant association between prescription of bendroflumethiazide and diagnosis of listeriosis (adjusted OR, 0.63; 95% CI, 0.37-1.09) for current use (Supplementary Table 3 ). Analysis for effect-measure modification revealed heterogeneity across strata of several variables including age, CMI, and glucocorticoids. Table 3 lists adjusted ORs for potential effect-measure modifiers. Sex and calendar year, which were not expected to be independent risk factors, had correspondingly homogenous effect measures across strata.
DISCUSSION
This large, registry-based, case-control study provides further evidence that PPI use is associated with an increased risk of listeriosis. After adjustment for comorbidity and other confounding factors, we found that current use of PPIs conferred an overall 2.8 times increase in the risk of acquiring invasive listeriosis. This association waned with time before diagnosis of listeriosis but remained statistically significant for use in the 3 months prior to diagnosis.
While it is likely that most people are exposed to listeria, on occasion, through the food, only predisposed individuals are likely to contract infectious listeriosis. A characteristic of listeriosis is that underlying illnesses, older age, or conditions that impair immunity are necessary risk factors for the development of listeriosis. Therefore, adjusting for host factors becomes the primary challenge in any analytical study of listeriosis. Here, we developed a comprehensive comorbidity index based on data from the entire Danish population from an 18½-year period. An alternative strategy would have been to use a propensity score-matched control group to provide a more homogenous study population. However, our data did not allow for such a design because access to data for 1 register was restricted. As expected, ORs were substantially changed when we adjusted for comorbidity status. We cannot exclude that residual confounding due to insufficient adjustment for comorbidity or frailty could still be present. However, we believe that our adjustment of comorbidity was thorough and as complete as obtainable. As expected, listeriosis patients had more comorbidities and received more medications than controls. In addition, as we expected, we found no association between bendroflumethiazide and listeriosis, which suggests that our design and statistical analyses were appropriate. Further, we found that the frailty of listeriosis patients cannot entirely explain the observed association with PPIs, as the ORs for the patient groups expected to include the least frail patients, namely, the youngest patients and patients with the lowest CMI score, remained statistically significant in the analysis of effect-measure modification. Due to the nature of a register-based, case-control study, we cannot exclude that the exposure to PPIs occurs concurrently with another unmeasured risk factor.
Overall, the comprehensive data from the Danish health registries are a strength of this study, providing valid and equal information on exposure and confounder variables on cases as well as controls. According to the RMPS, more than 97% of the total amount of PPIs sold during the study period were referable to a CPR number, and thus over-the-counter sales were negligible. We used prescription redemption as a proxy for use of medicine. Obviously, this could be a reason for bias, but we found no reason why differences in use of redeemed medicine should exist between controls and cases. Thus, it would result in a bias toward the null.
Based on the adjusted OR for current use of PPIs, we estimated a PAF of 8.3%. In comparison, Preußel et al found that a Exposure defined as redemption of prescription for proton pump inhibitors in the 30 days before index date. Percentage within stratum-specific cases and controls, respectively.
b Adjusted for comorbidity index, history of peptic ulcer, use of systemic glucocorticoids, and use of histamine-2-receptor antagonists.
c Likelihood ratio test for homogeneity of the odds ratios across strata within a variable.
d Percentiles as calculated from the distribution of comorbidity index scores of cases.
e Defined as a redemption of prescription up to 90 days before index date.
f Defined as a diagnosis of peptic ulcer within the last 12 months before index date.
gastric acid suppression within the last 3 months was associated with listeriosis, adjusted OR 2.96, and a corresponding PAF of 9.3% [10] . Also, others have suggested that the strongest association between PPIs and enteric infections is found among patients with a prescription date close to date of diagnosis; however, protopathic bias could have affected these studies [11, 12, 17] . We tried to limit this by setting the index date 7 days before the day of diagnosis of listeriosis. We did not calculate a dose-response pattern. However, we did look at first-time prescriptions within the previous year in current users and found that 37.2% of cases were first-time users. Thus, the majority of current users had received PPIs previously, which is supportive of the association not being a result of protopathic bias. Nonetheless, the proportion of first-time users was substantial. It could be speculated that commencement of PPI treatment induces an immediate period of increased vulnerability to infections. We found modification of ORs by some variables including age and CMI. Generally, effect-measure modification was observed within variables with large differences in risk of listeriosis between the different strata, for example, young people vs elderly people and low CMI score vs high CMI score. High ORs were observed at levels with low a priori risk of listeriosis. Among persons with a CMI score below the median, we found an OR of 4.94 (3.47-7.02) for current use of PPIs, whereas those with a CMI score above the 75% percentile had an OR of 1.18 (0.70-1.99). A plausible explanation is that effect-measure modification is dependent on the scale of the outcome measure [31] . Individual data may be generated from an additive mechanism that causes the same absolute change in risk but results in a higher relative impact for those with a low baseline risk. However, the effect-measure modification seen for glucocorticoids could be explained by a biological interaction because the patients who took glucocorticoids had significantly increased ORs compared with the patients who did not take glucocorticoids. We expected patients in treatment to have a higher a priori risk and consequently a relatively lower risk increase due to PPIs, but the opposite was the case in our study.
PPIs have been regarded as generally safe and without serious adverse effects. However, this perspective is changing. Based on evidence of increased risk of acute and chronic kidney disease, hypomagnesemia, bone fracture, CAP, and Clostridium difficile infection [32, 33] , the US Food and Drug Administration has published a safety alert concerning these potential adverse effects of PPI [34] . Several studies have put forward that PPI is a risk factor for listeriosis, and our study corroborates these findings. Further, we found a greater association for PPI than for H2RA, which is congruous with the findings in a systematic review by Leonard et al [35] on the association between acid suppression and enteric infections. Our study is observational, and we note that it does not provide proof of causality. Further, it cannot be excluded that people receiving PPI treatment receive more frequent medical attention, and this could lead to ascertainment bias. However, evidence is mounting that PPIs can have a biologic, causal effect on the risk of enteric infections including foodborne infections such as salmonellosis, campylobacteriosis, and listeriosis. PPIs reduce gastric acid secretion. It is hypothesized that this may enhance survival of acid-sensitive pathogens, including L. monocytogenes, when they pass through the stomach, thus increasing the risk of disease. Two recent studies that indicated that the gut microbiome is altered in PPI users substantiate this model [36, 37] . Notably, decreased bacterial diversity [36] and increased oral bacteria and potential pathogenic bacteria were found in PPI users' gut microbiota [36, 37] .
In conclusion, we found a temporal association between the use of PPIs and increased susceptibility to listeriosis after adjustment for confounders and underlying illness. Patients treated with glucocorticoids could have an increased risk of listeriosis when taking PPIs.
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